1188264-15-4

Basic information

• Product Name: (3-(4-bromophenyl)oxetan-3-yl)methanol
• Synonyms: (3-(4-bromophenyl)oxetan-3-yl)methanol;3-(4-bromophenyl)-3-Oxetanemethanol;3-(4-Bromophenyl)-3-(hydroxymethyl)oxetane
• CAS NO: 1188264-15-4
• Molecular Formula: C₁₀H₁₁BrO₂
• Molecular Weight: 243
• Mol File: 1188264-15-4.mol

Chemical Properties

• Boiling Point: 332.2±27.0 °C(Predicted)
• Appearance: /
• Density: 1.525±0.06 g/cm3(Predicted)
• PKA: 14.58±0.10(Predicted)
• CAS DataBase Reference: (3-(4-bromophenyl)oxetan-3-yl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (3-(4-bromophenyl)oxetan-3-yl)methanol(1188264-15-4)
• EPA Substance Registry System: (3-(4-bromophenyl)oxetan-3-yl)methanol(1188264-15-4)

Safety Data

• Hazardous Substances Data: 1188264-15-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(3-(4-bromophenyl)oxetan-3-yl)methanol is used as a key intermediate in the synthesis of pharmaceutical compounds for its unique structural features and reactivity, contributing to the development of new drugs with improved therapeutic properties.
Used in Chemical Synthesis:
In the chemical synthesis industry, (3-(4-bromophenyl)oxetan-3-yl)methanol serves as a valuable building block for creating a variety of complex organic molecules, leveraging its bromine atom for further functionalization and reactions.
Used in Materials Science:
(3-(4-bromophenyl)oxetan-3-yl)methanol is utilized in the development of advanced materials due to its distinctive structural attributes, potentially leading to innovations in areas such as polymers, coatings, and composites that require specific chemical and physical properties.
Used as a Reagent in Organic Synthesis:
(3-(4-bromophenyl)oxetan-3-yl)methanol is employed as a reagent in various organic reactions, taking advantage of its bromine-containing group for selective transformations and the introduction of functional groups into target molecules.

Upstream product

• 96-49-1 [1,3]-dioxolan-2-one 
• 936494-74-5 2-(4-bromophenyl)-2-(hydroxymethyl)propane-1,3-diol 
• 1878-68-8 2-(4-bromophenyl)-acetic acid 
• 93139-85-6 2-(4-bromophenyl)malonic acid diethyl ester 
• 1620017-14-2 {[3-(4-bromophenyl)oxetan-3-yl]methoxy}(tert-butyl)diphenylsilane 
• 1620017-13-1 2-(4-bromophenyl)-2-[(tert-butyldiphenylsilyloxy)methyl]propane-1,3-diol 
• 1620017-12-0 diethyl 2-(4-bromophenyl)-2-[(tert-butyldiphenylsilyloxy)methyl]malonate 
• 1620017-11-9 diethyl 2-(4-bromophenyl)-2-(hydroxymethyl)malonate 
• 1423702-61-7 C₁₂H₁₅BrO₄ 
• 14062-25-0 Ethyl 4-bromophenylacetate 

Downstream Products

• 1423702-65-1 methyl 3-(4-bromophenyl)oxetane-3-carboxylate 
• 1423702-68-4 methyl 3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)oxetane-3-carboxylate 
• 1423684-87-0 C₂₉H₂₆N₂O₆ 
• 1393585-20-0 3-(4-bromophenyl)oxetane-3-carboxylic acid 
• 1402465-20-6 (R)-3-(4'-(1-methyl-5-(((1-phenylethoxy)carbonyl)amino)-1H-pyrazol-4-yl)-[1,1'-biphenyl]-4-yl)oxetane-3-carboxylic acid 

Relevant articles and documents

Oxetane Promise Delivered: Discovery of Long-Acting IDO1 Inhibitors Suitable for Q3W Oral or Parenteral Dosing

3,3-Disubstituted oxetanes have been utilized as bioisosteres for gem-dimethyl and cyclobutane functionalities. We report the discovery of a novel class of oxetane indole-amine 2,3-dioxygenase (IDO1) inhibitors suitable for Q3W (once every 3 weeks) oral and parenteral dosing. A diamide class of IDO inhibitors was discovered through an automated ligand identification system (ALIS). Installation of an oxetane and fluorophenyl dramatically improved the potency. Identification of a biaryl moiety as an unconventional amide isostere addressed the metabolic liability of amide hydrolysis. Metabolism identification (Met-ID)-guided target design and the introduction of polarity resulted in the discovery of potent IDO inhibitors with excellent pharmacokinetic (PK) profiles in multiple species. To enable rapid synthesis of the key oxetane intermediate, a novel oxetane ring cyclization was also developed, as well as optimization of a literature route on kg scale. These IDO inhibitors may enable unambiguous proof-of-concept testing for the IDO1 inhibition mechanism for oncology.

Immunomodulator

The invention provides an immunomodulator, and belongs to the field of medical chemistry. The immunomodulator is a compound represented by formula I, or a stereoisomer, or a salt, or a solvate, or a prodrug, or a metabolite thereof. The compound disclosed by the invention shows good IL-17A inhibitory activity, can be used for preparing an IL-17A inhibitor, is used for treating diseases with abnormal IL-17A activity, and the invention provides a new medicinal possibility for clinically treating diseases related to abnormal IL-17A activity.

A new and versatile synthesis of 3-substituted oxetan-3-yl methyl alcohols

We have developed a novel route for the efficient synthesis of pharmaceutically significant 3-substituted oxetan-3-yl methyl alcohols starting from readily available malonates. The synthesis harnesses the diversity of malonate chemistry and allows access to a range of oxetanes, which exemplifies the versatility of this procedure.

A new and versatile synthesis of 3-substituted oxetan-3-yl methyl alcohols

We have developed a novel route for the efficient synthesis of pharmaceutically significant 3-substituted oxetan-3-yl methyl alcohols starting from readily available malonates. The synthesis harnesses the diversity of malonate chemistry and allows access to a range of oxetanes, which exemplifies the versatility of this procedure.

LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS

Compounds, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or diagnose diseases, disorders, or conditions associated with one or more of the lysophosphatidic acid receptors are provided.